MagPortal.com   "Clients return to our site because of the research capabilities provided by MagPortal.com — research that is not commonly found on most websites."
  – John Houston, SVP, Raymond James Financial Services
 Home  |  News Feeds  |  Stock Market  |  Newsletter  |  My Articles  |  My Account  |  Affiliate Program  |  Help 

Location: Categories / Business / Industries / Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.
See Also
Health
Health / Illness, Injury & Treatments
Health / Medical Practice
Science & Technology / Biology & Life Sciences
Current Medical Articles
BusinessWeek
November 19, 2009
Catherine Arnst
Why Drugmakers Don't Twitter The FDA has so far failed to craft rules clarifying how pharmaceutical companies can participate in online discussions. mark for My Articles similar articles
The Motley Fool
November 19, 2009
Brian Orelli
Pfizer Dodges a Bullet The drugmaker slips through an advisory committee unscathed. mark for My Articles similar articles
The Motley Fool
November 19, 2009
Brian Orelli
This Stock Is a Train Wreck Genzyme's string of missteps has investors nervous. mark for My Articles similar articles
The Motley Fool
November 19, 2009
Brian Orelli
Pfizer's Generic Growth, With a Side of Sashimi A move into Japan isn't a bad idea, but it isn't going to save the company either. mark for My Articles similar articles
Chemistry World
November 18, 2009
Sarah Houlton
A pharmaceutical named desire A new drug being developed by Boehringer Ingelheim could give a boost to the sex drive of women with low libido. mark for My Articles similar articles
The Motley Fool
November 18, 2009
Brian Orelli
Your Heart or Your Stomach? It must be disappointing to know that a label change on another drug -- one that isn't even your competition -- is going to hurt sales, but that's the position that Procter & Gamble and AstraZeneca find themselves in. mark for My Articles similar articles
The Motley Fool
November 18, 2009
Brian Orelli
Drug Lowers Cholesterol; Stock Follows ISIS has a hard time at American Heart Association despite good efficacy data. mark for My Articles similar articles
The Motley Fool
November 18, 2009
Brian Orelli
VIVUS Gets a Spark A new erectile-dysfunction drug shows promise. mark for My Articles similar articles
The Motley Fool
November 17, 2009
Brian Orelli
Up 80%, It's Time to Sell Bristol-Myers to Mead Johnson: It's time to walk on your own. Investors will have an option of exchanging some or all of their Bristol-Myers shares for shares in Mead Johnson for a slight discount mark for My Articles similar articles
The Motley Fool
November 17, 2009
Brian Orelli
This Partnership Is Smoking! Glaxo and Nabi team up for smokers who want to quit. Let's just hope they don't flame out in phase 3 trials. mark for My Articles similar articles
The Motley Fool
November 17, 2009
Dave Mock
A Big Upgrade for Sanofi-Aventis This bullish call comes from more than just one analyst. mark for My Articles similar articles
The Motley Fool
November 16, 2009
Brian Orelli
Music to Health-Care Investors' Ears Are faster FDA review times coming? mark for My Articles similar articles
The Motley Fool
November 16, 2009
Amanda B. Kish
The Hottest Sector for 2010 It's hard to argue that the potential benefits to this sector won't be significant if health care reform does work its way through. The time to stock up on high-quality health-care names is now. mark for My Articles similar articles
The Motley Fool
November 16, 2009
Brian Orelli
Abbott Puts a Nail in Merck's Coffin There's a clear winner from the American Heart Association conference. mark for My Articles similar articles
CRM
November 2009
Lauren McKay
Pharmaceuticals -- CRM Undergoes an Experimental New Treatment An older CRM vertical gets a new dose of on-demand technology. mark for My Articles similar articles
The Motley Fool
November 13, 2009
Brian Orelli
Abbott: Brave or Stupid? Abbott Labs announces the acquisition of PanGenetics' pain drug PG110, which is still in phase 1 trials. mark for My Articles similar articles
The Motley Fool
November 13, 2009
Brian Orelli
Questioning Pfizer's Integrity Pfizer's epilepsy drug Neurontin has had generic competition for a few years, but it's still plaguing the pharmaceutical giant. mark for My Articles similar articles
BusinessWeek
November 12, 2009
Catherine Arnst
10 Ways to Cut Health-Care Costs Right Now Employers and hospitals don't have to wait for Congress to address inefficiencies and waste. mark for My Articles similar articles
The Motley Fool
November 12, 2009
Brian Orelli
How Do You Say 'Drug Development' in Mandarin? Drug giant Novartis announces that it's heading to China in a big way. mark for My Articles similar articles
The Motley Fool
November 12, 2009
Brian Orelli
The Life-and-Death Situation That Isn't Branded-drug makers aren't playing fair because they refuse to sell samples to generic drug makers. mark for My Articles similar articles
The Motley Fool
November 12, 2009
Kris Eddy
Drug Companies Should Think Smaller Sanofi-aventis looks to break R&D into smaller chunks; their collaboration with Regeneron Pharmaceuticals is a good example of the new strategy. mark for My Articles similar articles
The Motley Fool
November 11, 2009
Robert Steyer
There Will Be Blood (Plasma) Talecris Biotherapeutics Holdings introduces itself to investors with a bloody good third quarter. mark for My Articles similar articles
The Motley Fool
November 11, 2009
Jim Mueller
This Company Is a Value Stock! Isn't It? A look at Boston Scientific leads to conflicting conclusions. mark for My Articles similar articles
The Motley Fool
November 11, 2009
Brian Orelli
Now That's What I Call a Drug Deal Investors are regenerating their interest in Regeneron Pharmaceuticals after it extended its drug-discovery pact with sanofi-aventis. mark for My Articles similar articles
The Motley Fool
November 10, 2009
Brian Orelli
Small Acquisitions and the Road to Success Bristol-Myers is taking a different route to bulk up. It announced licensing of a phase 2 rheumatoid arthritis drug, ALD518, from privately held Alder Biopharmaceuticals. mark for My Articles similar articles
The Motley Fool
November 10, 2009
Brian Orelli
3 Companies Looking for Gratitude Early These three small drug companies all have PDUFA dates in the next week: Cadence Pharmaceuticals... NeurogesX... Genzyme... mark for My Articles similar articles
The Motley Fool
November 9, 2009
Brian Orelli
Guidant: The Gift That Keeps on Giving And not in the good way. Last year, Boston Scientific took a whopping $2.7 billion goodwill writedown because it had to downgrade the value of what it got in acquiring Guidant. mark for My Articles similar articles
The Motley Fool
November 9, 2009
Brian Orelli
Health-Care Reform: A Tale of Two Chambers Halfway done, but the battle is just heating up. mark for My Articles similar articles
The Motley Fool
November 9, 2009
Dave Mock
A Big Upgrade for Gilead Sciences The biopharmaceutical company moves up to a five star rating from Motley Fool analysts. mark for My Articles similar articles
BusinessWeek
November 4, 2009
Arlene Weintraub
Ask Your Doctor If This Ad Is Right for You The drug industry is spending billions on TV ads, but they may be scaring consumers away mark for My Articles similar articles
HBS Working Knowledge
November 5, 2009
Michel Anteby
A Market for Human Cadavers in All but Name? Addressing the shortage of cadavers for medical education and training, Harvard Business School professor Michel Anteby discusses issues around establishing a market for cadavers. mark for My Articles similar articles
The Motley Fool
November 5, 2009
Brian Orelli
Slow Down There, Merck Merck CEO Richard Clark says his company is looking to do more deals than ever, perhaps "even try to double" the current rate of 50 per year. mark for My Articles similar articles
Chemistry World
November 4, 2009
Phil Taylor
New treatment hope for lupus patients GlaxoSmithKline and Human Genome Sciences' Benlysta (belimumab), works by blocking the production of autoantibodies by plasma B-cells, the immune system's primary antibody-producing cells. mark for My Articles similar articles
The Motley Fool
November 4, 2009
Brian Orelli
An Ode to Schering-Plough Mergers and acquisitions in the pharmaceutical industry are cataloged in a poem. mark for My Articles similar articles
The Motley Fool
November 4, 2009
Brian Orelli
This One Is Thriving in a Recession Saving customers money makes it easy for Medco. mark for My Articles similar articles
The Motley Fool
November 3, 2009
Brian Orelli
Nice Quarter, Teva. What Will You Buy Next? Branded or generic, it's always a tough call. mark for My Articles similar articles
The Motley Fool
November 3, 2009
Brian Orelli
A Little Distracted, Are You, Merck? The FDA rejects its latest application. mark for My Articles similar articles
The Motley Fool
November 3, 2009
Rich Smith
Is BABY Back? Natus Medical beat earnings, but can it continue to top the S&P 500? mark for My Articles similar articles
The Motley Fool
November 3, 2009
Brian Orelli
Amylin Scores a Hat Trick Amylin Pharmaceuticals got a triple dose of good news over the weekend. mark for My Articles similar articles
The Motley Fool
November 3, 2009
Rich Smith
This Just In: Upgrades and Downgrades Needham suspends clinical trial of buying Geron. mark for My Articles similar articles
Chemistry World
October 23, 2009
Matt Wilkinson
What's in a pill? Buying cheap drugs over the internet is well known to be a risky business. But the sinister menace of the 'falsified' active pharmaceutical ingredient gets far less publicity. mark for My Articles similar articles
Fast Company
November 2009
David H. Freedman
The Gene Bubble: Why We Still Aren't Disease-Free When the human genome was first sequenced nearly a decade ago, the world lit up with talk about how new gene-specific drugs would help us cheat death. Well, the verdict is in: Keep eating those greens. mark for My Articles similar articles
Fast Company
November 2009
Stephanie Schomer
Lost Dollars in Gene Research Billions of R&D dollars flowed to companies promising to cure our ills. Most of those companies are now dead or forgotten. mark for My Articles similar articles
MyBusiness
Oct/Nov 2009
What's On Your Mind? A look at some of the public opinion polls shows what was on your mind this summer. mark for My Articles similar articles
MyBusiness
Oct/Nov 2009
Bob Graboyes
Beyond 2009: The Three Big M's No one should underestimate their power of Medicare, Medicaid and malpractice to make or break small businesses in the not-too-distant future. mark for My Articles similar articles
There are 6209 old articles available for this category.